BioWorld Has Been Acquired by Thomson Reuters

    BioWorld and its companion publication Medical Device Daily (MDD) have been acquired by Thomson Reuters, the world’s leading source of intelligent information for businesses and professionals.

    We’re interested in joining Thomson Reuters because we believe it will allow us to further invest in innovation and to grow our offerings. As you may know, Thomson Reuters is also the provider of Cortellis. Thomson Reuters CortellisSM is a single source of pharmaceutical intelligence with flexible delivery options for quicker, more-informed decision making.

    Bringing the BioWorld portfolio into Thomson Reuters will strengthen our publications by giving our journalists access to all the information Thomson Reuters captures on the industry. The news and industry perspective published by BioWorld and MDD will likewise strengthen the information, analytics and insight Thomson Reuters delivers to its customers.

    Customers should be assured that it is business as usual throughout the transition, and that you will continue to enjoy the same great offerings you’ve come to expect from BioWorld and MDD. In addition, as a BioWorld and MDD customer you will benefit from the Thomson Reuters superior service, global resources and rich expertise along with integrated access to a broad range of content including: clinical trials, pharmacology, systems biology, patents, investigational drugs, and conference reports.

    Both BioWorld and Thomson Reuters are delighted by this new opportunity.